Late-Stage R&D and Bioproduction Unit Team

Late-stage R&D, scale-up and technology transfer for complex biopharmaceuticals production.

Research Focus

At iBET’s Late-stage R&D and Bioproduction Unit, we are dedicated to advancing bioprocess solutions for some of the most complex biopharmaceuticals.

Our work spans a diverse range of modalities, including viral vectors such as adeno-associated virus (AAVs), oncolytic or chimeric viruses, recombinant proteins like virus-like particles (VLPs), next-generation antibodies (e.g. bi- and tri-specific formats), and difficult-to-express antigens, including antibody fragments and receptor domains.

The team has been reinforcing iBET’s leadership in these areas, nationally and internationally, while also fostering interaction amongst iBET Units/laboratories and the training of specialized researchers and technicians. Most recent activities have been centered on the design of robust solutions for product expression, purification and characterization, process scale-up (up to 50 L), and technology transfer to GMP environments.

For more details, please visit our dedicated Late-Stage R&D and Bioproduction Unit page.

Areas of Activity

Late-stage R&D

We design and optimize upstream and downstream processes, integrating advanced bioanalytical tools and continuous bioprocessing strategies to ensure robust performance and product quality.

Bioprocess Scale-up

We translate lab-scale processes into scalable, GMP compliant processes for production and purification of complex biopharmaceuticals.

Technology Transfer

We deliver seamless transfer to CDMOs through comprehensive documentation, SOP development, and on-site shadowing of key process operations.

Late Stage R&D
Technology transfer

Team Members